pemafibrate
Kowa Pharmaceuticals
[]
the prominent trial presented today at #aha2022 revealed that in patients with diabetes, mild to moderate hypertriglyceridemia and low hdl, pemafibrate did not lower rates of cv disease. 
Cardiovascular Medicine Fellow @BrighamWomens @HarvardMed | Research Fellow @TIMIStudyGroup | Forbes 30 Under 30 | Proud Alum @Caltech